Essential Partners’s ImmunityBio IBRX Stock Holding History

Essential Partners’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$928	Hold	106	–	–	﹤0.01%	2276
2026 Q1	$813	Hold	106	–	–	﹤0.01%	2303
2025 Q4	$210	Sell	106 -12	-10%	-$27	﹤0.01%	2423
2025 Q3	$290	Sell	118 -30	-20%	-$77	﹤0.01%	2328
2025 Q2	$391	Buy	+148	New	+$398	﹤0.01%	1767

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Essential Partners's IBRX Position: Q2 2026 in Review

Essential Partners held its ImmunityBio (IBRX) position steady in Q2 2026 at 106 shares worth $928. The position accounts for ﹤0.01% of the portfolio, ranked #2276.

Essential Partners first reported a position in IBRX in Q2 2025 and has held it in 5 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Essential Partners held 106 shares of ImmunityBio worth $928 as of Q2 2026.
Essential Partners left its ImmunityBio share count unchanged in Q2 2026.
ImmunityBio made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2276 holding.
Essential Partners first reported a position in ImmunityBio in Q2 2025 and has held it in 5 quarters since.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.